Chemotherapy before standard treatment for high-risk nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether adding chemotherapy before the usual radiation and chemotherapy treatment can improve outcomes for people with a certain type of nasopharyngeal cancer that has higher risk features. It aims to see if the extra treatment helps control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have nasopharyngeal cancer that has spread to lymph nodes in the neck (stage T3N1M0).
- You are between 18 and 70 years old.
- You have at least one high-risk feature, such as large lymph nodes, multiple lymph nodes, or a high EBV DNA level in your blood.
- You are generally well enough to carry out daily activities (ECOG score 0 or 1).
- Your blood counts and liver and kidney function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different chemotherapy combinations given before radiation for nasopharyngeal cancer. It is for patients with advanced but not metastatic disease who are in good overall health.
This trial compares two approaches for people with early-stage nasopharyngeal cancer that can be removed with surgery. It tests whether giving less intense chemotherapy and radiation after surgery works as well as a standard dose, with fewer side effects.
This trial compares two treatment plans for newly diagnosed, operable nasopharyngeal cancer: adding surgery plus targeted chemoradiation versus standard chemoradiation alone. It aims to see whether the surgery-based plan improves control of the cancer and related outcomes.
This trial tests whether taking the chemo tablet capecitabine after standard chemoradiation can help prevent cancer from coming back, and whether adding an immune therapy (a PD-1 antibody) improves results. It is for people with high-risk nasopharyngeal (throat) cancer whose main treatment has already finished.
This trial tests a combination of chemotherapy (three drugs: docetaxel, cisplatin, and fluorouracil) plus an immunotherapy drug (a PD-1 inhibitor, which helps your immune system fight cancer) given before the standard radiation treatment for nasopharyngeal cancer. The goal is to see if this upfront treatment can improve outcomes in patients whose cancer has not spread to distant parts of the body.
This trial compares two treatment options for people with nasopharyngeal cancer that did not respond well to initial chemotherapy. One option is to switch to a different chemotherapy regimen, the other is to go straight to radiation therapy. The study aims to see which approach is more effective in this situation.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.